Maynard Um
-
-
-
-
-
-
-
Ocugen (OCGN) Misses Q1 EPS by 1c
-
-
-
-
-
-
-
Lucid Capital Markets Starts Ocugen, Inc. (OCGN) at Buy
-
-
-
-
-
-
-
Ocugen (OCGN) Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Trial of OCU410ST
-
-
-
-
-
-
-
Ocugen (OCGN) Tops Q4 EPS by 1c
-
-
-
-
-
-
-
Ocugen (OCGN) Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400
-
-
-
-
-
-
-
Ocugen (OCGN) Announces Removal of Clinical Hold on OCU200
-
-
-
-
-
-
-
Increasing unusual put option volume: PTEN BMBL NXE FYBR BIG ALNY FND OCGN
-
448,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

